Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | December 31, 2019 | January 03, 2020 |
| EAGLE PHARMACEUTICALS, INC.EGRX · Entity 85958 | 10% owner | February 28, 2024 | March 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date December 31, 2019 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2029-12-31 | Direct | 50,562 |
Reported balance
After 2019-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-31 · Grant · Acquired 50,562 · Balance 50,562 F1: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date.
EAGLE PHARMACEUTICALS, INC.
Report date February 28, 2024 · Filed March 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 460,621 |
Reported balance
After 2024-02-28 transaction · row 1
1 source rowRow 1 · 2024-02-28 · Tax withholding · Disposed 2,119 · Balance 460,621 F1: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 | 992,623 |
Reported balance
Holding disclosure · report date 2024-02-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 992,623 F2: Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024.
F2: Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theriva Biologics, Inc.
Report date November 11, 2020 · Filed November 12, 2020
Section 16 reporting ended · disclosed 2020-11-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 16:40 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 2,119 | $6.27 | $13,286.13 |
DisclosureSEC source: 0000950170-24-023945 · ownership.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,621 F1 · shares: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on February 28, 2024. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 16:44 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 3,154 | $6.44 | $20,311.76 |
DisclosureSEC source: 0000950170-24-023198 · ownership.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,740 F3 · shares: The disposition reported on this Form 4 represents shares of Common Stock withheld by the Issuer to cover the tax liability upon the vesting of PSUs on February 27, 2024 and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 16:44 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 12,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-023198 · ownership.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,894 F1 · shares: Represents shares of Common Stock received upon vesting of performance stock units ("PSUs") that were granted on February 2, 2021. F1 · price: Represents shares of Common Stock received upon vesting of performance stock units ("PSUs") that were granted on February 2, 2021. F2 · balance_after: Reflects the transfer of 88,181 shares of Common Stock pursuant to a Rule 16a-12 transaction. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 17:00 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 4,322 | $5.13 | $22,171.86 |
DisclosureSEC source: 0000950170-24-003397 · ownership.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 541,125 F1 · shares: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units on January 5, 2024. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 16:39 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 10,694 | $13.87 | $148,325.78 |
DisclosureSEC source: 0001209191-23-054333 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 545,447 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.20 inclusive. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 16:39 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 10,925 | $13.82 | $150,983.50 |
DisclosureSEC source: 0001209191-23-054333 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 556,141 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.64 to $14.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 710 | $15.11 | $10,728.10 |
DisclosureSEC source: 0001209191-23-052030 · doc4.xml · nonDerivative · entry 3 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,066 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $15.18 inclusive. Read SEC document |
| October 03, 2023 Filed Oct 4, 2023 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 10,024 | $14.41 | $144,445.84 |
DisclosureSEC source: 0001209191-23-052030 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567,776 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.09 to $15.05 inclusive. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 9,511 | $15.23 | $144,852.53 |
DisclosureSEC source: 0001209191-23-052030 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,800 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.035 to $15.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| May 16, 2023 Filed May 18, 2023 17:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 15,000 | $19.98 | $299,700.00 |
DisclosureSEC source: 0001209191-23-030725 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 587,311 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.7454 to $20.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This report reflects an adjustment to the Reporting Person's direct holdings to exclude shares incorrectly included in prior reports as directly held and to reflect such shares as held indirectly through the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust"). Read SEC document |
| May 15, 2023 Filed May 15, 2023 20:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 200 | $21.52 | $4,304.00 |
DisclosureSEC source: 0001209191-23-029625 · doc4.xml · nonDerivative · entry 5 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,594,934 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.525 inclusive. Read SEC document |
| May 15, 2023 Filed May 15, 2023 20:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 14,800 | $21.06 | $311,688.00 |
DisclosureSEC source: 0001209191-23-029625 · doc4.xml · nonDerivative · entry 4 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,595,134 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.4867 to $21.43 inclusive. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 11,869 | $20.42 | $242,364.98 |
DisclosureSEC source: 0001209191-23-029625 · doc4.xml · nonDerivative · entry 3 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,609,934 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.745 inclusive. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 3,131 | $19.69 | $61,649.39 |
DisclosureSEC source: 0001209191-23-029625 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,621,803 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $20.11 inclusive. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:34 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 15,000 | $20.71 | $310,650.00 |
DisclosureSEC source: 0001209191-23-029625 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,624,934 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $20.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5). Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 16:18 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 70,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014646 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,639,934 F2 · shares: Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of March 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:18 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 3,113 | $28.00 | $87,164.00 |
DisclosureSEC source: 0001209191-23-014646 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,569,034 F1 · kind: The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| January 23, 2023 Filed Jan 24, 2023 18:13 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 3,732 | $33.64 | $125,544.48 |
DisclosureSEC source: 0001209191-23-004680 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,572,147 F1 · kind: The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 16:33 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 3,827 | $29.26 | $111,978.02 |
DisclosureSEC source: 0001209191-23-002566 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575,879 F1 · kind: The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 18:02 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 34,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015009 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579,706 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of February 28, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:54 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 31,201 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001209191-21-025187 · doc4.xml · derivative · entry 4 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,201 shares Expires 2021-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:54 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 16,278 | $41.87 | $681,559.86 |
DisclosureSEC source: 0001209191-21-025187 · doc4.xml · nonDerivative · entry 3 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,544,906 F1 · kind: Represents shares withheld to pay exercise price and to satisfy withholding tax obligations. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:54 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock | 31,201 | $8.78 | $273,944.78 |
DisclosureSEC source: 0001209191-21-025187 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Apr 5, 2021 16:54 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GiftCommon Stock | 16,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025187 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529,983 Read SEC document |
| January 23, 2021 Filed Jan 26, 2021 18:31 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 4,631 | $47.70 | $220,898.70 |
DisclosureSEC source: 0001209191-21-005495 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,546,323 F1 · kind: Represents shares withheld to satisfy withholding tax obligations. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:17 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 7,548 | $57.98 | $437,633.04 |
DisclosureSEC source: 0001209191-20-004990 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,954 F1 · kind: Represents shares withheld to satisfy withholding tax obligations. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:29 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantEmployee Stock Option (right to buy) · Derivative | 145,700 | $0.00 Strike: $59.80 | $0.00 |
DisclosureSEC source: 0001209191-20-002360 · doc4.xml · derivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,700 Underlying: Common Stock · 145,700 shares Expires 2030-01-04 F3 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 5, 2021, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:29 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 58,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002360 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,558,502 F1 · shares: Represents restricted stock units ("RSUs"). The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 5, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:11 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 50,562 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-20-001186 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,562 Underlying: Common Stock · 50,562 shares Expires 2029-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 12:13 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 250,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-19-070376 · tm1923941d5_form4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2026-12-04 F1 · shares: These stock options vest as follows: 1/3 will vest on the one year anniversary of the grant date, 1/3 will vest on the two year anniversary of the grant date and the remaining 1/3 will vest on the three year anniversary of the grant date. F1 · derivative.exercise_date: These stock options vest as follows: 1/3 will vest on the one year anniversary of the grant date, 1/3 will vest on the two year anniversary of the grant date and the remaining 1/3 will vest on the three year anniversary of the grant date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:33 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommn Stock | 24,975 | $50.15 | $1,252,496.25 |
DisclosureSEC source: 0001209191-19-023147 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,202 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 16:31 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 12,428 | $51.81 | $643,894.68 |
DisclosureSEC source: 0001209191-19-015645 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,525,177 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.3201 to $52.2003 inclusive. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 16:31 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 12,000 | $50.51 | $606,120.00 |
DisclosureSEC source: 0001209191-19-015645 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.1615 to $51.0577 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 20:04 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 900 | $42.30 | $38,070.00 |
DisclosureSEC source: 0001209191-19-007134 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,549,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.18 to $42.49 inclusive. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 20:04 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 29,185 | $41.52 | $1,211,761.20 |
DisclosureSEC source: 0001209191-19-007134 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,550,505 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.18 to $42.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantEmployee Stock Option (right to buy) · Derivative | 137,200 | $0.00 Strike: $42.40 | $0.00 |
DisclosureSEC source: 0001209191-19-005447 · doc4.xml · derivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,200 Underlying: Common Stock · 137,200 shares Expires 2029-01-23 F3 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 23, 2020, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 20:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantCommon Stock | 61,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-005447 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579,690 F1 · shares: Represents restricted stock units ("RSUs"). The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the one, two, three and four-year anniversaries of January 23, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 21:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 302 | $40.57 | $12,252.14 |
DisclosureSEC source: 0001209191-19-002391 · doc4.xml · nonDerivative · entry 5 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,390 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.36 to $40.78 inclusive. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 21:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 5,670 | $39.70 | $225,099.00 |
DisclosureSEC source: 0001209191-19-002391 · doc4.xml · nonDerivative · entry 4 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.46 to $40.35 inclusive. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 21:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 10,597 | $39.04 | $413,706.88 |
DisclosureSEC source: 0001209191-19-002391 · doc4.xml · nonDerivative · entry 3 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,524,362 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.46 to $39.04 inclusive. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 8,500 | $40.03 | $340,255.00 |
DisclosureSEC source: 0001209191-19-002391 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534,959 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.63 to $40.53 inclusive. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:22 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock | 6,500 | $39.30 | $255,450.00 |
DisclosureSEC source: 0001209191-19-002391 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,543,459 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.63 to $39.615 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:18 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 126,700 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001209191-19-000590 · doc4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,700 Underlying: Common Stock · 126,700 shares Expires 2028-12-31 F1 · derivative.exercise_date: 126,700 options vest on 12/31/2019. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:01 UTC | Theriva Biologics, Inc. SYN · Entity 7919 | GrantStock Options · Derivative | 79,500 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001144204-18-063625 · tv508642_4.xml · derivative · entry 1 Tarriff Scott · CIK 0001469124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2025-12-06 F1 · shares: These options will vest monthly on a pro rata basis over 36 consecutive months. F1 · derivative.exercise_date: These options will vest monthly on a pro rata basis over 36 consecutive months. Read SEC document |
| June 28, 2018 Filed Jul 3, 2018 17:09 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionStock Option (Right to Buy) · Derivative | 124,804 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001209191-18-041189 · doc4.xml · derivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,804 shares Expires 2019-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on April 2, 2010 and the remainder vested in equal monthly installments over a period of three years ending April 2, 2013. Read SEC document |
| June 28, 2018 Filed Jul 3, 2018 17:09 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock | 124,804 | $4.04 | $504,208.16 |
DisclosureSEC source: 0001209191-18-041189 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,549,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 17:05 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 113,104 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001209191-18-023136 · doc4.xml · derivative · entry 3 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,104 shares Expires 2018-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 17:05 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Tax withholdingCommon Stock | 57,895 | $52.69 | $3,050,487.55 |
DisclosureSEC source: 0001209191-18-023136 · doc4.xml · nonDerivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,425,155 F1 · shares: Represents shares withheld to pay exercise price and to satisfy withholding tax obligations. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 17:05 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | Exercise / conversionCommon Stock | 113,104 | $4.04 | $456,940.16 |
DisclosureSEC source: 0001209191-18-023136 · doc4.xml · nonDerivative · entry 1 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2018 Filed Jan 9, 2018 17:50 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | GrantPeformance Stock Unit · Derivative | 189,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003005 · doc4.xml · derivative · entry 2 Tarriff Scott · CIK 0001469124 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,000 Underlying: Common Stock · 189,000 shares Expires 2021-01-01 F2 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · shares: Represents the maximum number of shares issuable under this award. F4 · derivative.exercise_date: The shares issuable in respect of such PSUs shall vest on the three-year anniversary of January 1, 2018 (such three-year anniversary, the "Vesting Date"), based on the extent to which the following stock price hurdles are achieved for 30 consecutive trading days on or prior to the Vesting Date. If the Issuer's stock price reaches or surpasses $85.92, $110.00, $120.00 or $134.25, then 63,000, 126,000, 157,500 or 189,000 PSUs will vest, respectively. The number of shares issuable in respect of such PSUs vested on the Vesting Date will be determined by the highest Issuer stock price hurdle achieved. This vesting is subject to the Reporting Person's continuous service with the Issuer as of the Vesting Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.